SION

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cystic fibrosis by directly stabilizing a protein domain called NBD1 within the CFTR protein, which is defective in CF patients. The company is focusing on the F508del genetic mutation, which is present in approximately 90% of CF patients, and is using structural biology and screening to optimize drug candidates designed to work alone or in combination with other CFTR modulators. Sionna's approach targets a mechanism that existing CF therapies do not address, aiming to restore CFTR function closer to normal levels in patients who currently lack adequate treatment options.

Pipeline

Catalyst Calendar